Rybelsus 3, 7 and 14 mg posted to the FDA discontinuation list
The FDA's drug shortage database now lists all three original Rybelsus tablet strengths as "To Be Discontinued," confirming Novo Nordisk is winding down the first oral GLP-1 pill sold in the US.
The FDA's drug shortage database shows three entries for Rybelsus (oral semaglutide) tablets, all marked "To Be Discontinued" as of June 4, 2026 [1]. The listings cover the drug's original three strengths, and the database's total result count for semaglutide tablet records is three, matching the 3 mg, 7 mg and 14 mg doses Rybelsus has sold in since its 2019 approval [1]. The manufacturer is listed as Novo Nordisk Pharmaceutical Industries, LP, with the parent company shown as Novo Nordisk, Inc. [1].
For the 14 mg strength, the FDA record lists a discontinued date of June 4, 2026, and an initial posting date of the same day, with the update type marked "New" [1]. The presentation is described simply as "Rybelsus, Tablet, 14 mg (NDC 0169-4314-30)" [1]. The FDA's related-information field states: "Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets" [1]. Ozempic has historically been sold only as an injectable pen, so what a tablet version of Ozempic actually is, or how it differs from Rybelsus, is not explained in this record and is not yet known from the sources available [1].
The database entry lists a contact phone number, 833-493-4689, for questions about the discontinuation, along with the drug's original approval number, NDA213051 [1]. The underlying openFDA dataset was last updated September 14, 2026, meaning the discontinuation status shown reflects information collected some months after the June posting date [1].
Why it matters for patients
A "To Be Discontinued" listing in the FDA shortage database means the manufacturer plans to stop making the drug, not that pharmacies have already run out [1]. Patients currently filling prescriptions for Rybelsus 3 mg, 7 mg or 14 mg may still find supply for a period, but the listing signals that refills could eventually become harder to find as existing stock is used up. The database does not say when supplies will actually run dry, so patients should not assume a specific date for when Rybelsus will disappear from pharmacy shelves.
The stated plan to replace Rybelsus with "Ozempic (semaglutide) tablets" raises real questions the FDA record does not answer [1]. Ozempic is semaglutide, the same active ingredient as Rybelsus, but it has always been an injectable product. Whether this reference means a new tablet formulation under the Ozempic name, a labeling change, or something else is not explained in the source, and no other detail about dosing, availability, or timing for this replacement product appears in the FDA record [1].
For people who prefer a pill over an injection, this development matters because Rybelsus has been the only FDA-approved oral GLP-1 medication on the market since 2019. If it is discontinued without a clear oral replacement, patients who rely on it may need to discuss alternatives with their prescriber, including other oral or injectable GLP-1 options, though the sources here do not compare those choices or their costs.
What happens next
The FDA shortage database was last updated on September 14, 2026, with the discontinuation entries still showing a status of "To Be Discontinued" as of the original June 4, 2026 posting [1]. No further government or company statement is included in this record clarifying a firm end date for Rybelsus supply, pricing for any tablet-form Ozempic product, or a transition timeline for current patients. Those details are not yet known based on the available source.
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.